Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB000631 in healthy volunteers
NCT07039929Phase 1Terminated
- Sponsor
- Incyte
- Start
- Jul 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INCB000631 (6 cohorts), sponsored by Incyte. Primary endpoints: Treatment-emergent Adverse Events at 2.5 months, Maximum Plasma Concentration at Day 18 and 7 more. Started Jul 2025; status: terminated.
02
Drugs
INCB000631
Beyond the preview
Go deeper on NCT07039929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07039929.